type 3 VWD have a severe bleeding tendency characterized not only by mucocutaneous hemorrhages (epistaxis, menorrhagia, and gastrointestinal bleeding) but also by hemarthroses and hematomas, as in moderately severe hemophilia.
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The mainstays of treatment of VWD include autologous replacement therapy with the synthetic drug desmopressin (DDAVP) and allogeneic replacement therapy with plasmaderived VWF/FVIII or VWF concentrates devoid of FVIII.
12,13
While most patients with type 1 VWD (i.e., usually those with FVIII and VWF basal levels higher than 10 U/dL) respond to DDAVP, the majority of patients with type 2 and type 3 VWD are unresponsive to this drug and thus require infusions of VWF-containing concentrates.
14 Following these infusions, approximately 5 to 10% of patients with type 3 VWD develop alloantibodies against VWF; affected patients can present with a variety of symptoms, ranging from a loss of hemostatic response to infused VWF concentrates to anaphylactic reactions in rare cases. [15] [16] [17] This narrative review is dedicated to such alloantibodies and their management.
Alloantibodies in Type 3 VWD
Although inhibitory VWF alloantibodies have been reported anecdotally in type 2B VWD, 18 this severe complication has been almost exclusively described in patients with type 3 VWD.
Characteristics of VWF Alloantibodies
Since the description of the first patient with VWD alloantibodies in 1974 by Sarji Pertaining to the inhibitor diagnosis, the presence of an anti-VWF antibody should be suspected by a poor VWF recovery and/or rapid clearance after infusion of VWF-containing concentrates. A pharmacokinetic study should therefore be performed periodically in all patients with type 3 VWD, particularly in carriers of high-risk VWF mutations.
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Although the anti-VWF antibodies do not demonstrate a dependence on time and/or temperature, a negative mixing test (performed at 37°C with an incubation between 15 minutes and 2 hours) does not rule out the presence of a VWF inhibitor, because these may be directed against nonfunctional epitopes.
17 Similarly, the use of an enzyme-linked immunosorbent assay (ELISA) to detect the inhibitor is considered unreliable due to the high rate of false-positive results. 28, 29 Anti-VWF antibodies, which are titrated in Bethesda units, are polyclonal IgGs, most commonly belonging to the IgG4 subclass and exhibit a wide range of epitope recognition on VWF molecule. 30, 31 The most striking feature of some anti-VWF antibodies, particularly those with higher titer, is their ability to precipitate VWF with immune complex-mediated activation of the complement system, responsible for life-threatening anaphylactic reactions following re-exposure to VWF.
32-34

Management of VWF Alloantibodies
For those patients with type 3 VWD who develop alloantibodies, plasma-derived concentrates containing VWF must be avoided because these often cause life-threatening anaphylactic reactions. reported the successful use of recombinant FVIII (a bolus dose of 60 IU/kg followed by 25 IU/kg/hour) to prevent bleeding in a child undergoing orthopaedic surgery. The use of recombinant FVIII (a bolus dose of 100 IU/kg followed by 35 IU/kg/hour) was also successfully used for the management of delivery, performed through cesarean section, in another alloimmunized patient with type 3 VWD. 37 Notably, the fact that patients with type 3 VWD with anti-VWF alloantibodies can be safely and effectively operated using recombinant FVIII products (►Table 1) suggests that the control of surgery-related bleeding depends primarily on plasma FVIII coagulant activity (FVIII:C). Thus, considering Alloantibodies in VWD Franchini, Mannucci 591
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that functional levels of VWF (VWF ristocetin cofactor, VWF: RCo) remain unmeasurable in plasma throughout the postinfusion period due to the neutralizing action of alloantibodies, we advise to monitor FVIII:C levels postoperatively in such patients.
40,41
As previously mentioned, an additional therapeutic option includes the use of a bypassing agent, such as recombinant FVIIa. 42, 43 Due to the limited experience in this clinical setting, the dosage and regimen used has been borrowed from those utilized in patients with congenital hemophilia A and inhibitors. 44 A few studies have demonstrated that recombinant FVIIa, at a starting bolus dose of 100 to 200 μg/kg followed by 90 μg/kg every 2 hours or at 20 μg/kg/hour by continuous intravenous infusion, is able to provide an effective surgical hemostasis in patients with type 3 VWD having anti-VWF antibodies. 45, 46 The sequential combination of recombinant FVIII and FVIIa has also been attempted by some investigators 37,39 to improve their hemostatic efficacy without adverse events. The use of platelet concentrates for treatment or prevention of bleeding in type 3 VWD with alloantibodies is another attractive therapeutic option that deserves to be explored in future studies. This rationale is based on the fact that differing from VWD patients' platelets, transfused normal platelets contain normal amounts of VWF in their α granules, where it is protected from alloantibodies in the plasma and transported and released directly at the sites of vascular injury, where it can exert its hemostatic action locally. 47 Finally, a case of successful immune tolerance in a 9-year-old boy with type 3 VWD and inhibitors has been described. In this patient, before FVIII/VWF concentrate infusions (Haemate P, CSL Behring; 100 IU/kg e.o.d.), premedication with hydroxyzine (20 mg) and methylprednisolone (1 mg/kg) together with monthly IV immunoglobulins (single dose, 0.8 g/kg) for 3 months was administered without allergic reactions or anamnestic inhibitor response.
39
Conclusion
Although a minority of patients with type 3 VWD form alloantibodies to exogenous VWF, the arising complications are challenging, as these antibodies render replacement VWF therapy ineffective, and in some cases, dangerous by producing anaphylactic reactions upon re-exposure. The identification of VWF mutations at higher inhibitor risk leads us to suggest that genetic investigation of newly diagnosed children with type 3 VWD for mutations predisposing to alloantibody formation is valuable before starting extensive therapy with exogenous VWF concentrates. 17, 23 In patients at risk of mutations, the first few infusions of VWF/FVIII concentrates should be preferably administered in hospital until it is clear that antibodies with the related risk of severe postinfusion reactions have not occurred. Diagnosis and treatment of patients with anti-VWF alloantibodies is challenging due to the lack of standardized laboratory methods for their identification and few literature data on treatment, respectively. Traditional mixing studies are not reliable as a screening test to detect an inhibitor in patients with type 3 VWD, and thus it is necessary to perform measurements of in vivo recovery and survival of infused VWF when an inhibitor is suspected. Finally, limited but favorable experience with the infusion of the hemostatic recombinant agents FVIII (administered by continuous intravenous infusion at high doses) and FVIIa exist, which can be used for the prevention or treatment of bleeding in patients with complications.
